Literature DB >> 21838844

The impact of clinical and demographic variables on cognitive performance in methamphetamine-dependent individuals in rural South Carolina.

Kimber L Price1, Stacia M DeSantis, Annie N Simpson, Bryan K Tolliver, Aimee L McRae-Clark, Michael E Saladin, Nathaniel L Baker, Mark T Wagner, Kathleen T Brady.   

Abstract

Inconsistencies in reports on methamphetamine (METH) associated cognitive dysfunction may be attributed, at least in part, to the diversity of study sample features (eg, clinical and demographic characteristics). The current study assessed cognitive function in a METH-dependent population from rural South Carolina, and the impact of demographic and clinical characteristics on performance. Seventy-one male (28.2%) and female (71.8%) METH-dependent subjects were administered a battery of neurocognitive tests including the Test of Memory Malingering (TOMM), Shipley Institute of Living Scale, Paced Auditory Serial Addition Test (PASAT), Symbol Digit Modalities Test (SDMT), Grooved Pegboard Test, California Verbal Learning Test (CVLT), and Wisconsin Card Sorting Test (WCST). Demographic and clinical characteristics (eg, gender, frequency of METH use) were examined as predictors of performance. Subjects scored significantly lower than expected on one test of attention and one of fine motor function, but performed adequately on all other tests. There were no predictors of performance on attention; however, more frequent METH use was associated with better performance for males and worse for females on fine motor skills. The METH-dependent individuals in this population exhibit very limited cognitive impairment. The marked differences in education, Intellectual Quotient (IQ), and gender in our sample when compared to the published literature may contribute to these findings. Characterization of the impact of clinical and/or demographic features on cognitive deficits could be important in guiding the development of treatment interventions. © American Academy of Addiction Psychiatry.

Entities:  

Mesh:

Year:  2011        PMID: 21838844      PMCID: PMC3603567          DOI: 10.1111/j.1521-0391.2011.00164.x

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  50 in total

1.  The neuropsychological test performance of drug-abusing patients: an examination of latent cognitive abilities and associated risk factors.

Authors:  William Fals-Stewart; Marsha E Bates
Journal:  Exp Clin Psychopharmacol       Date:  2003-02       Impact factor: 3.157

2.  Findings of preserved implicit attention in methamphetamine dependent subjects.

Authors:  Ruth Salo; Martin H Leamon; Yutaka Natsuaki; Charles Moore; Christy Waters; Thomas E Nordahl
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-08-19       Impact factor: 5.067

3.  A behavioral analysis of degree of reinforcement and ease of shifting to new responses in a Weigl-type card-sorting problem.

Authors:  D A GRANT; E A BERG
Journal:  J Exp Psychol       Date:  1948-08

4.  Frontal glucose hypometabolism in abstinent methamphetamine users.

Authors:  Seog Ju Kim; In Kyoon Lyoo; Jaeuk Hwang; Young Hoon Sung; Ho Young Lee; Dong Soo Lee; Do-Un Jeong; Perry F Renshaw
Journal:  Neuropsychopharmacology       Date:  2005-07       Impact factor: 7.853

5.  Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence.

Authors:  N D Volkow; L Chang; G J Wang; J S Fowler; D Franceschi; M Sedler; S J Gatley; E Miller; R Hitzemann; Y S Ding; J Logan
Journal:  J Neurosci       Date:  2001-12-01       Impact factor: 6.167

6.  Neuropsychological function and delay discounting in methamphetamine-dependent individuals.

Authors:  William F Hoffman; Meredith Moore; Raymond Templin; Bentson McFarland; Robert J Hitzemann; Suzanne H Mitchell
Journal:  Psychopharmacology (Berl)       Date:  2006-08-17       Impact factor: 4.530

7.  Neuroprotective effects of estradiol in the adult rat hippocampus: interaction with insulin-like growth factor-I signalling.

Authors:  I Azcoitia; A Sierra; L M Garcia-Segura
Journal:  J Neurosci Res       Date:  1999-12-15       Impact factor: 4.164

8.  Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET.

Authors:  Y Sekine; M Iyo; Y Ouchi; T Matsunaga; H Tsukada; H Okada; E Yoshikawa; M Futatsubashi; N Takei; N Mori
Journal:  Am J Psychiatry       Date:  2001-08       Impact factor: 18.112

9.  A dissociation in attentional control: evidence from methamphetamine dependence.

Authors:  Ruth Salo; Thomas E Nordahl; Charles Moore; Christy Waters; Yutaka Natsuaki; Gantt P Galloway; Shawn Kile; Edith V Sullivan
Journal:  Biol Psychiatry       Date:  2005-02-01       Impact factor: 13.382

10.  Impaired prefrontal cortical function and disrupted adaptive cognitive control in methamphetamine abusers: a functional magnetic resonance imaging study.

Authors:  Ruth Salo; Stefan Ursu; Michael H Buonocore; Martin H Leamon; Cameron Carter
Journal:  Biol Psychiatry       Date:  2009-01-12       Impact factor: 13.382

View more
  14 in total

Review 1.  Cognitive enhancement as a treatment for drug addictions.

Authors:  Mehmet Sofuoglu; Elise E DeVito; Andrew J Waters; Kathleen M Carroll
Journal:  Neuropharmacology       Date:  2012-06-23       Impact factor: 5.250

2.  Dysregulation of D₂-mediated dopamine transmission in monkeys after chronic escalating methamphetamine exposure.

Authors:  Stephanie M Groman; Buyean Lee; Emanuele Seu; Alex S James; Karen Feiler; Mark A Mandelkern; Edythe D London; J David Jentsch
Journal:  J Neurosci       Date:  2012-04-25       Impact factor: 6.167

3.  Neuroadaptations in the dentate gyrus following contextual cued reinstatement of methamphetamine seeking.

Authors:  Yoshio Takashima; McKenzie J Fannon; Melissa H Galinato; Noah L Steiner; Michelle An; Alice E Zemljic-Harpf; Sucharita S Somkuwar; Brian P Head; Chitra D Mandyam
Journal:  Brain Struct Funct       Date:  2018-02-13       Impact factor: 3.270

4.  Methamphetamine differentially affects BDNF and cell death factors in anatomically defined regions of the hippocampus.

Authors:  M H Galinato; L Orio; C D Mandyam
Journal:  Neuroscience       Date:  2014-11-26       Impact factor: 3.590

5.  Targeting white matter neuroprotection as a relapse prevention strategy for treatment of cocaine use disorder: Design of a mechanism-focused randomized clinical trial.

Authors:  Joy M Schmitz; Scott D Lane; Michael F Weaver; Ponnada A Narayana; Khader M Hasan; DeLisa D Russell; Robert Suchting; Charles E Green
Journal:  Contemp Clin Trials       Date:  2021-10-22       Impact factor: 2.226

6.  Substance use and mental health characteristics associated with cognitive functioning among adults who use methamphetamine.

Authors:  Diane M Herbeck; Mary-Lynn Brecht
Journal:  J Addict Dis       Date:  2013

Review 7.  An evaluation of the evidence that methamphetamine abuse causes cognitive decline in humans.

Authors:  Andy C Dean; Stephanie M Groman; Angelica M Morales; Edythe D London
Journal:  Neuropsychopharmacology       Date:  2012-09-05       Impact factor: 7.853

Review 8.  Sex differences in methamphetamine use disorder perused from pre-clinical and clinical studies: Potential therapeutic impacts.

Authors:  Atul P Daiwile; Subramaniam Jayanthi; Jean Lud Cadet
Journal:  Neurosci Biobehav Rev       Date:  2022-04-20       Impact factor: 9.052

9.  The Bay Area Verbal Learning Test (BAVLT): Normative Data and the Effects of Repeated Testing, Simulated Malingering, and Traumatic Brain Injury.

Authors:  David L Woods; John M Wyma; Timothy J Herron; E William Yund
Journal:  Front Hum Neurosci       Date:  2017-01-12       Impact factor: 3.169

Review 10.  Evaluating Exercise as a Therapeutic Intervention for Methamphetamine Addiction-Like Behavior.

Authors:  Sucharita S Somkuwar; Miranda C Staples; McKenzie J Fannon; Atoosa Ghofranian; Chitra D Mandyam
Journal:  Brain Plast       Date:  2015-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.